enzalutamide

Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy, Department of Urology and Research Program in Systems Oncology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland, Instituto Valenciano de Oncologia, Valencia, Spain, Astellas Pharma Inc., Northbrook, IL, Pfizer Inc., New York, NY,

Clinical trial

An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Status: Active (not recruiting), Estimated PCD: 2015-09-20

Clinical trial

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting, Estimated PCD: 2026-04-15

Clinical trial

An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2019-04-10

Clinical trial

An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Prospective, Multi-Country, Observational Study of Clinical Outcomes for Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With ADT Plus Apalutamide or Enzalutamide Under Routine Clinical Practice (ArtemisPRO)

Status: Recruiting, Estimated PCD: 2025-09-05

Clinical trial

A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Status: Terminated, Estimated PCD: 2019-01-12

Clinical trial

The Registry to Observe Clinical Outcomes of Patients With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

Use of Darolutamide, Enzalutamide and Apalutamide for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - EXTension of the DEAR Real-world Study (NCT05362149)

Status: Active (not recruiting), Estimated PCD: 2024-05-31

Clinical trial

A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)

Status: Completed, Estimated PCD: 2022-01-14

Clinical trial

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features

Status: Active (not recruiting), Estimated PCD: 2023-04-07

Clinical trial

STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

Status: Active (not recruiting), Estimated PCD: 2026-03-01

Clinical trial

Monitoring the Neurological Toxicity of Enzalumatide Through VigiBase, a Pharmacovigilance Study

Status: Completed, Estimated PCD: 2023-01-01

Clinical trial

A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3

Status: Completed, Estimated PCD: 2023-05-03

Clinical trial

Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study

Status: Completed, Estimated PCD: 2017-10-01

Clinical trial

CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer

Status: Completed, Estimated PCD: 2018-04-01

Clinical trial

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2022-01-31

Clinical trial

A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2025-08-31

Clinical trial

Phase II Trial of Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Status: Recruiting, Estimated PCD: 2028-12-31

Abstract

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.

Org: Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, UCI Health,

Abstract

mFAST-SeqS based aneuploidy score in circulating cell-free DNA and role as early response marker in patients with metastatic prostate cancer treated with androgen receptor signaling inhibitor.

Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Franciscus Gasthuis & Vlietland, Erasmus University Medical Center,

Clinical trial

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS

Status: Terminated, Estimated PCD: 2022-03-30

Clinical trial

Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer

Status: Completed, Estimated PCD: 2016-12-31